Privi Speciality Chemicals shares declined as much as 13.00% following the execution of a major block deal worth ₹1,086.00 crores. The transaction involved 38.80 lakh shares, representing 9.93% of the company's outstanding equity, executed at an average price of ₹2,799.00 per share.

Block Deal Execution and Market Impact

The completed transaction exceeded the initially announced deal parameters, demonstrating significant institutional participation:

The execution price of ₹2,799.00 per share came below the initially indicated price range of ₹2,835.00 to ₹2,850.00, representing an 11.10% discount to the previous day's closing price.

Transaction Scale Evolution

The actual block deal significantly exceeded initial projections:

The substantial increase in transaction size from ₹700.00 crores to ₹1,086.00 crores indicates expanded divestment by the promoter entity.

Shareholding Structure

The company maintains a concentrated ownership structure with strong promoter presence:

Promoters held 69.89% stake as of the September quarter, with over 26,000 retail shareholders holding up to ₹2.00 lakh authorized share capital maintaining an 8.70% stake.

Performance Context

Despite the current decline, the stock maintains strong annual performance:

The stock has gained 65.00% in the current calendar year, marking its best performance since 2021 when it recorded gains of over 240.00%.

Privi Speciality Chemicals Limited has announced the approval of a fresh scheme of amalgamation involving its subsidiaries Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited. The Board of Directors approved the new scheme during a meeting held on December 19, 2025, from 3:00 p.m. to 5:00 p.m., as disclosed in their regulatory filing to BSE and NSE.

Background of Corporate Restructuring

This development follows the company's earlier withdrawal of a similar amalgamation scheme in November 2025. The Board had previously withdrawn the scheme based on observations received from stock exchanges, with plans to refile the application shortly. The company has now fulfilled that commitment with the approval of this comprehensive new scheme under Sections 230 to 232 of the Companies Act, 2013.

Details of the Amalgamation Scheme

The approved scheme involves the amalgamation of Privi Fine Sciences Private Limited (PFSPL) and Privi Biotechnologies Private Limited (PBPL) with Privi Speciality Chemicals Limited. The scheme is subject to approvals from shareholders, creditors, the National Company Law Tribunal (NCLT), and other regulatory authorities as required under applicable laws.

Financial figures as of September 30, 2025 (Standalone basis)

Share Exchange Ratio and Consideration

Under the scheme, no cash consideration is proposed. The share exchange mechanism is structured with specific ratios based on independent valuations.

Business Operations and Strategic Rationale

Privi Fine Sciences operates two manufacturing units - one operational facility in Lote, Chiplun, Maharashtra, and a second unit in Jhagadia, Gujarat, spanning 152,444.46 square meters for green science business. The company is currently conducting pilot-level tests for products developed through in-house research using green science chemistry.

Privi Biotechnologies focuses on biotechnology products and research & development for fragrances, flavours, and preservatives. The amalgamation aims to create operational synergies, reduce administrative costs, and enhance market competitiveness through consolidated operations.

Expected Post-Amalgamation Shareholding

The scheme will result in changes to the shareholding pattern of Privi Speciality Chemicals:

The transaction falls within the ambit of related party transactions but is conducted on an arm's length basis, supported by independent valuations and fairness opinions. The company has submitted the required disclosures in compliance with SEBI regulations, marking a significant step forward in its corporate restructuring initiative.